diagnostics

Amarantus Subsidiary Merging into Avant Diagnostics to Streamline Assets

Amarantus Bioscience Holdings, Inc., and Avant Diagnostics recently announced they have entered into a Letter of Intent (LOI) to merge Amarantus Diagnostics, an Amarantus-owned subsidiary, into Avant Diagnostics. The merger is being undertakenĀ to advance the commercial development of diagnostic assets in the fields of oncology and neurology, includingĀ thoseĀ specifically…

MSPrecise Shown to be Accurate in Diagnosing RRMS in Study Cohort

A new study testingĀ Amarantus Diagnostics’Ā MSPrecise on multiple sclerosisĀ patients identified the test as a specific and sensitive diagnostic test for multiple sclerosis. The test accurately diagnosed 84% of multiple sclerosis patients from a broad range of subjectsĀ with potential neurological diseases. These results further support Amarantus Diagnostics’ ability to design next generation…

Innovative “Nanoprobe” Used to Diagnose Multiple Sclerosis

A nanometric sensor — an extremely small probe originally designed to test samples for the presence of herbicides, heavy metals, and pollutants — was experimentally shown to also detect molecules commonly associated with multiple sclerosis. Physicist FĆ”bio de Lima Leite, a professor at the Federal University of SĆ£o Carlos (UFSCar),…

Diagnostic System by Luoxis Can Detect Oxidative Stress in MS

Luoxis Diagnostics, Inc. recently presented three clinical and preclinical findings that feature the company’s proprietaryĀ RedoxSYSā„¢ Diagnostic System as a comprehensive, groundbreaking tool for research capable of assessing a patient’sĀ oxidation-reduction potential (ORP) in the event ofĀ injury, illness, or stress.Ā The findings were presented as peer-reviewed posters during the recently concludedĀ …